Lamotrigine과 Aripiprazole을 투여한 환자에서 발생한 과민성 반응 1예
Hypersensitivity Reaction in a Patient Treated with Lamotrigine and Aripiprazole : A Case Report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
lamotrigine은 양극성 장애에서의 뛰어난 항우울 효과로 사용이 증가 추세인 약물이지만 피부 발진 및 AHS라는 중요한 부작용을 가질 수 있는데, 그 경과는 본 증례에서와 같이 다양하며, 약물 투여 중단 및 과민반응 치료 시작 후에도 상당기간 지속되거나 심지어 이후에 새로 나타날 수도 있다. 이렇게 넓은 임상 경과 스펙트럼을 보이므로, lamotrigine 사용 중 원인이 밝혀지지 않은 전신 증상 및 피부 증상이 발생할 경우 되도록 빨리 투약을 중단하고, 투약 중단 후 조심스럽고도 면밀한 임상 경과의 추적 관찰이 적어도 수주일 이상 필요할 것으로 생각된다.
Abstract
We described a case of a 30-year-old female patient with bipolar disorder who experienced the anticonvulsant hypersensitivity syndrome (AHS) during treatment with lamotrigine and aripiprazole. She developed fever (38.4℃), leukopenia, skin rash, and elevated serum transaminase levels on the 11th day of lamotrigine treatment (20th day of aripiprazole). Hypersensitivity to lamotrigine was suspected;lamotrigine was discontinued and prednisolone (30 mg/day) was administered to the patient. The clinical manifestations and laboratory findings showed improvement. However, on the 11th day of lamotrigine discontinuation (7th day of prednisolone treatment), she developed maculopapular skin rash over the entire body except the mucosa. There were no other symptoms and the laboratory findings were within normal limits. Skin biopsy showed erythema multiforme. After prescribing 55 mg/day of predisolone for additional 8 days, the recovery was uneventful, and it took 4 weeks from the onset of the second skin rash. Lamotrigine induced AHS showed broad spectrum of presentation and some manifestations can be flared up several days after discontinuation as did in this case. If unexplained systemic symptoms or a skin rash of unknown cause develop during the use of lamotrigine, clinicians should discontinue lamotrigine promptly and monitor the patient carefully at least for several weeks. (J Korean Neuropsychiatr Assoc 2006;45(4):387-391)
참고문헌 (8)
- "Prescribing information: Lamictal" (2005)
- "Safety and tolerability of lamotrigine for bipolar disorder", 27, pp.173~184 (2004)
- "Safety review of adult clinical trial experience with lamotrigine", 18, pp.281~296 (1998)
- "Rash in multicenter trials of lamotrigine in mod disorders: clinical relevance and management", 63, pp.1012~1019 (2002)
- "Rash in adult and pediatric patients treated with lamotrigine", 25, pp.14~18 (1998)
- "Lamotrigine: a review of its use in bipolar disorder", 63, pp.2029~2050 (2003)
- "Anticonvulsant hypersen-sitivity syndrome: incidence, prevention and management", 21, pp.489~501 (1999)
- "ran-domised comparison between lamotrigine and carbamazepine in"
